BRAF V600E突变在高危甲状腺结节且细胞学良性结果中的价值
本研究纳入720例患者共787个高危甲状腺结节,先行超声引导下细针穿刺,对细胞学良性者追加BRAF V600E突变检测。292个细胞学良性结节中36个突变阳性,其中31个经病理证实为恶性;作者推荐对具有≥2个超声可疑特征的高危甲状腺结节,细针穿刺应常规联合BRAF V600E突变检测。
要点
- 细胞学良性结节中BRAF V600E阳性者36个,其中31个病理证实为恶性。
- 36个突变阳性结节中25个(69.4%)有≥2个超声可疑特征,11个(30.6%)有1个。
- 作者推荐高危结节具≥2个超声可疑特征时,细针穿刺应常规联合BRAF V600E检测。
核心结论
- BRAF V600E突变检测可发现细针穿刺可能漏诊的甲状腺乳头状癌;作者推荐对具有≥2个超声可疑特征的高危甲状腺结节,细针穿刺应常规联合BRAF V600E突变检测。
研究设计与样本
- 研究纳入720例患者共787个高危结节,均行超声引导下细针穿刺,对细胞学良性结节追加BRAF V600E突变检测,并以最终病理确认细胞学良性且突变阳性的结节;对细胞学良性且突变阴性的结节行超声随访,结节增大或超声特征改变者重复细针穿刺。
关键影像表现/征象
- 787个结节中292个细胞学结果为良性,其中256个BRAF V600E突变阴性、36个突变阳性。
- 36个突变阳性结节中25个(69.4%)具有≥2个超声可疑特征,11个(30.6%)具有1个超声可疑特征。
诊断标准与关键数值
- 细胞学良性且BRAF V600E突变阳性的36个结节中,31个经病理证实为恶性、5个证实为良性。
- 对11个增大且BRAF V600E突变阴性的细胞学良性结节重复细针穿刺,结果为4个良性、2个滤泡性肿瘤或疑似滤泡性肿瘤、3个疑似恶性、2个恶性。
临床应用与阅片要点
- 对细胞学良性但BRAF V600E突变阳性的高危甲状腺结节,应依据最终病理确认恶性。
- 对细胞学良性且BRAF V600E突变阴性的结节,超声随访中结节增大或超声特征改变者应重复细针穿刺。
- 作者推荐细针穿刺应常规联合BRAF V600E突变检测用于具有≥2个超声可疑特征的高危甲状腺结节。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Limitations of ultrasound-guided fine-needle aspiration include nondiagnostic, indeterminate cytology and false-negative results. The BRAF V600E mutation is a specific biomarker for papillary thyroid carcinoma. This study aimed to investigate the additional diagnostic role of the BRAF V600E mutation in high-risk thyroid nodules with benign cytology results.
MATERIALS AND METHODS: A total of 787 high-risk nodules in 720 patients underwent ultrasound-fine-needle aspiration. A subsequent BRAF V600E mutation test was performed on thyroid nodules with benign cytology. Final pathology confirmed thyroid nodules with benign cytology that were positive for the BRAF V600E mutation. Ultrasound was performed on thyroid nodules with benign cytology results that were negative for the BRAF V600E mutation. Fine-needle aspiration was repeated on thyroid nodules with enlarged size or changed ultrasound features.
RESULTS: Among the 787 nodules, 292 thyroid nodules had benign cytology results with 256 nodules negative for the BRAF V600E mutation and 36 nodules positive for the BRAF V600E mutation. Thirty-one nodules positive for the BRAF V600E mutation were confirmed malignant, and 5 nodules were confirmed benign by pathology. Fine-needle aspiration was repeated on 11 enlarged thyroid nodules with benign cytology findings that were negative for the BRAF V600E mutation. The results of repeat fine-needle aspiration were 4 benign nodules, 2 follicular neoplasms or suspected follicular neoplasms, 3 suspected malignancies, and 2 malignant nodules. Among the 36 thyroid nodules positive for the BRAF V600E mutation, 25 (69.4%) had ≥2 suspicious ultrasound features and 11 (30.6%) nodules had 1 suspicious ultrasound feature.
CONCLUSIONS: The BRAF V600E mutation test can detect papillary thyroid carcinomas that might be missed by fine-needle aspiration. We recommend that fine-needle aspiration be routinely accompanied by the BRAF V600E mutation test in high-risk thyroid nodules with ≥2 suspicious ultrasound features.
引用
- Chen X, Zhou Q, Wang F, et al. Value of BRAF V600E in High-Risk Thyroid Nodules with Benign Cytology Results. AJNR Am J Neuroradiol. 2018. PMID: 30498021. doi:10.3174/ajnr.A5898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。